Ezetimib/simvastatin kombinált terápia biztonsá gossága és hatékonysága 2-es típusú diabeteses, nem alkoholos zsírmájú betegekben

Translated title of the contribution: Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease

Tatjána Ábel, J. Fehér, E. Dinya, Mohamed Gamal Eldin, Attila Kovács

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease is commonly associated with type 2 diabetes, dyslipidemia and obesity all of which are components of the metabolic syndrome. Aim: To determine the efficacy and safety of ezetimibe/simvastatin 10/20mg combination therapy on patients with type 2 diabetes and nonalcoholic fatty liver disease. Methods: We studied nineteen patients with type 2 diabetes and nonalcoholic fatty liver disease diagnosed and treated between 2005 and 2008 at Health Center of Budaörs. After six months of ezetimibe/simvastatin (10/20mg/day) combination treatment, all patients were assessed for changes serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. Results: Six months of ezetimibe/simvastatin administration reduced significantly the serum levels of ALT (63.78±5.12 vs 32.57±3.92 U/L; p <0.0001), AST (50.79±3.66 vs 23.68±3.42 U/L; p <0.0001), cholesterol (6.26±0.46 vs 4.02±0.31 mmol/L; p <0.0001) and LDL-cholesterol (4.24±0.37 vs 2.22±0,1 mmol/L; p <0.0001). Combination therapy reduced significantly serum triglyceride level (2.62+0.48 vs 1.33+0.20 mmol/L; p <0.0001) and increased the level of HDL-cholesterol (1.02±0.12 vs 1.18±0.07 mmol/L; p <0.0001). Conclusions: These findings indicate that ezetimibe/simvastatin combination therapy is safe and effective in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Original languageHungarian
Pages (from-to)989-993
Number of pages5
JournalOrvosi Hetilap
Volume150
Issue number21
DOIs
Publication statusPublished - May 1 2009

Fingerprint

Type 2 Diabetes Mellitus
Simvastatin
Safety
Aspartate Aminotransferases
Alanine Transaminase
LDL Cholesterol
Serum
HDL Lipoproteins
Therapeutics
Dyslipidemias
HDL Cholesterol
Triglycerides
Obesity
Cholesterol
Non-alcoholic Fatty Liver Disease
Simvastatin Drug Combination Ezetimibe
Health
Ezetimibe

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ezetimib/simvastatin kombinált terápia biztonsá gossága és hatékonysága 2-es típusú diabeteses, nem alkoholos zsírmájú betegekben. / Ábel, Tatjána; Fehér, J.; Dinya, E.; Gamal Eldin, Mohamed; Kovács, Attila.

In: Orvosi Hetilap, Vol. 150, No. 21, 01.05.2009, p. 989-993.

Research output: Contribution to journalArticle

@article{c8322a500c31432f9722362df1482dd8,
title = "Ezetimib/simvastatin kombin{\'a}lt ter{\'a}pia biztons{\'a} goss{\'a}ga {\'e}s hat{\'e}konys{\'a}ga 2-es t{\'i}pus{\'u} diabeteses, nem alkoholos zs{\'i}rm{\'a}j{\'u} betegekben",
abstract = "Nonalcoholic fatty liver disease is commonly associated with type 2 diabetes, dyslipidemia and obesity all of which are components of the metabolic syndrome. Aim: To determine the efficacy and safety of ezetimibe/simvastatin 10/20mg combination therapy on patients with type 2 diabetes and nonalcoholic fatty liver disease. Methods: We studied nineteen patients with type 2 diabetes and nonalcoholic fatty liver disease diagnosed and treated between 2005 and 2008 at Health Center of Buda{\"o}rs. After six months of ezetimibe/simvastatin (10/20mg/day) combination treatment, all patients were assessed for changes serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. Results: Six months of ezetimibe/simvastatin administration reduced significantly the serum levels of ALT (63.78±5.12 vs 32.57±3.92 U/L; p <0.0001), AST (50.79±3.66 vs 23.68±3.42 U/L; p <0.0001), cholesterol (6.26±0.46 vs 4.02±0.31 mmol/L; p <0.0001) and LDL-cholesterol (4.24±0.37 vs 2.22±0,1 mmol/L; p <0.0001). Combination therapy reduced significantly serum triglyceride level (2.62+0.48 vs 1.33+0.20 mmol/L; p <0.0001) and increased the level of HDL-cholesterol (1.02±0.12 vs 1.18±0.07 mmol/L; p <0.0001). Conclusions: These findings indicate that ezetimibe/simvastatin combination therapy is safe and effective in patients with type 2 diabetes and nonalcoholic fatty liver disease.",
keywords = "Cardiovascular risk, Fatty liver, Hyperlipidemia",
author = "Tatj{\'a}na {\'A}bel and J. Feh{\'e}r and E. Dinya and {Gamal Eldin}, Mohamed and Attila Kov{\'a}cs",
year = "2009",
month = "5",
day = "1",
doi = "10.1556/OH.2009.28624",
language = "Hungarian",
volume = "150",
pages = "989--993",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "21",

}

TY - JOUR

T1 - Ezetimib/simvastatin kombinált terápia biztonsá gossága és hatékonysága 2-es típusú diabeteses, nem alkoholos zsírmájú betegekben

AU - Ábel, Tatjána

AU - Fehér, J.

AU - Dinya, E.

AU - Gamal Eldin, Mohamed

AU - Kovács, Attila

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Nonalcoholic fatty liver disease is commonly associated with type 2 diabetes, dyslipidemia and obesity all of which are components of the metabolic syndrome. Aim: To determine the efficacy and safety of ezetimibe/simvastatin 10/20mg combination therapy on patients with type 2 diabetes and nonalcoholic fatty liver disease. Methods: We studied nineteen patients with type 2 diabetes and nonalcoholic fatty liver disease diagnosed and treated between 2005 and 2008 at Health Center of Budaörs. After six months of ezetimibe/simvastatin (10/20mg/day) combination treatment, all patients were assessed for changes serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. Results: Six months of ezetimibe/simvastatin administration reduced significantly the serum levels of ALT (63.78±5.12 vs 32.57±3.92 U/L; p <0.0001), AST (50.79±3.66 vs 23.68±3.42 U/L; p <0.0001), cholesterol (6.26±0.46 vs 4.02±0.31 mmol/L; p <0.0001) and LDL-cholesterol (4.24±0.37 vs 2.22±0,1 mmol/L; p <0.0001). Combination therapy reduced significantly serum triglyceride level (2.62+0.48 vs 1.33+0.20 mmol/L; p <0.0001) and increased the level of HDL-cholesterol (1.02±0.12 vs 1.18±0.07 mmol/L; p <0.0001). Conclusions: These findings indicate that ezetimibe/simvastatin combination therapy is safe and effective in patients with type 2 diabetes and nonalcoholic fatty liver disease.

AB - Nonalcoholic fatty liver disease is commonly associated with type 2 diabetes, dyslipidemia and obesity all of which are components of the metabolic syndrome. Aim: To determine the efficacy and safety of ezetimibe/simvastatin 10/20mg combination therapy on patients with type 2 diabetes and nonalcoholic fatty liver disease. Methods: We studied nineteen patients with type 2 diabetes and nonalcoholic fatty liver disease diagnosed and treated between 2005 and 2008 at Health Center of Budaörs. After six months of ezetimibe/simvastatin (10/20mg/day) combination treatment, all patients were assessed for changes serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. Results: Six months of ezetimibe/simvastatin administration reduced significantly the serum levels of ALT (63.78±5.12 vs 32.57±3.92 U/L; p <0.0001), AST (50.79±3.66 vs 23.68±3.42 U/L; p <0.0001), cholesterol (6.26±0.46 vs 4.02±0.31 mmol/L; p <0.0001) and LDL-cholesterol (4.24±0.37 vs 2.22±0,1 mmol/L; p <0.0001). Combination therapy reduced significantly serum triglyceride level (2.62+0.48 vs 1.33+0.20 mmol/L; p <0.0001) and increased the level of HDL-cholesterol (1.02±0.12 vs 1.18±0.07 mmol/L; p <0.0001). Conclusions: These findings indicate that ezetimibe/simvastatin combination therapy is safe and effective in patients with type 2 diabetes and nonalcoholic fatty liver disease.

KW - Cardiovascular risk

KW - Fatty liver

KW - Hyperlipidemia

UR - http://www.scopus.com/inward/record.url?scp=66149132171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149132171&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28624

DO - 10.1556/OH.2009.28624

M3 - Article

C2 - 19443308

AN - SCOPUS:66149132171

VL - 150

SP - 989

EP - 993

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 21

ER -